Bone marrow failure

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Retrieved on: 
Friday, March 15, 2024

The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.

Key Points: 
  • The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.
  • The ongoing investigator initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab as a potential treatment for FA patients in bone marrow failure.
  • Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery.
  • “We’d like thank our collaborators at Stanford Medicine for their work evaluating briquilimab in this vulnerable patient population.”

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Retrieved on: 
Tuesday, April 2, 2024

“The acceptance of the MAA for RP-L102 marks an important step forward in our goal of bringing this potential gene therapy treatment to patients impacted by this devastating childhood disorder.

Key Points: 
  • “The acceptance of the MAA for RP-L102 marks an important step forward in our goal of bringing this potential gene therapy treatment to patients impacted by this devastating childhood disorder.
  • Currently, there are no existing options to potentially prevent BMF for patients with FA,” said Kinnari Patel, Pharm.D., MBA, President, Head of R&D and Chief Operating Officer, Rocket Pharma.
  • The safety profile was highly favorable with no significant safety signals, and the treatment, administered without any cytotoxic conditioning, was well tolerated.
  • The Biologics License Application (BLA) for FA remains on track for submission to the U.S. Food and Drug Administration (FDA) in the first half of 2024.

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024

Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter.

Key Points: 
  • Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter.
  • Total operating expenses for the fourth quarter of 2023 were $39.8 million compared to $48.2 million for the third quarter of 2023.
  • Interest expense during the fourth quarter of 2023 was $7.1 million compared to $7.9 million during the prior quarter.
  • During the fourth quarter of 2023, we earned $3.4 million in interest and other income compared to $4.4 million in the third quarter.

Your skin is a mirror of your health – here’s what yours might be saying

Retrieved on: 
Tuesday, January 30, 2024

It is the largest and most visible organ in the human body.

Key Points: 
  • It is the largest and most visible organ in the human body.
  • Being the most visible of our organs, the skin also offers us a view into the body tissues that it protects.
  • So don’t think of your skin merely aesthetically – think of it as a reflection of your health.

Bullseye

  • But while the vast majority of tick bites won’t make you ill, there is one rash that should prompt a visit to your doctor if you spot it.
  • Erythema migrans, a rash named for its ability to rapidly expand across the skin, is a hallmark of Lyme disease, a potentially severe bacterial illness.
  • This rash forms a classic target pattern, like a bullseye on a dartboard.

Purpura

  • Some rashes are given a colourful namesake – purpura is one such example.
  • Purpura refers to a rash of small purple or red dots.
  • Purpura signals an issue with either the walls of the tiny blood vessels that feed the skin or the blood within them.

Skin spiders


Skin rashes can also take on recognisable shapes. Spider naevi represent an issue within skin arterioles (small arteries which supply the skin with blood). Arterioles open and close to control the loss of heat from the body’s surface. But sometimes they can get stuck open – and a spider-like pattern will appear.

  • Crush the body under a fingertip and the whole thing disappears, as your touch temporarily stops the blood flow.
  • Treat the underlying cause, and the spiders often vanish with time – though they may persist or reappear later.

Black velvet

  • This “black velvet” skin appearance is more commonly seen in darker skins.
  • Usually, the condition is associated with disorders of the metabolism – namely type 2 diabetes and polycystic ovary syndrome.

Butterfly rashes

  • Cardiac valves have the important role of correctly directing the journey of blood through the heart and preventing backflow.
  • The body’s natural response is to preserve core blood volume, shutting off flow towards the skin.
  • The net effect can produce a purple-red rash, high across the cheeks and the bridge of the nose, like the outstretched wings of a butterfly.


Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Wednesday, December 20, 2023

“Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.

Key Points: 
  • “Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.
  • Every year, roughly 500 patients in the U.S. are diagnosed with PNH.3 An estimated 10-16 cases per million patients around the world have PNH.
  • Most patients are diagnosed with PNH in their 30s and 40s.
  • Please see the full Prescribing Information for Fabhalta, including Boxed WARNING and Medication Guide.®

Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium

Retrieved on: 
Thursday, September 21, 2023

The data will be featured in a presentation at the 2023 Fanconi Anemia Research Fund (FARF) Scientific Symposium, taking place on September 28 – October 1, 2023, in Vancouver, Canada.

Key Points: 
  • The data will be featured in a presentation at the 2023 Fanconi Anemia Research Fund (FARF) Scientific Symposium, taking place on September 28 – October 1, 2023, in Vancouver, Canada.
  • The ongoing investigator initiated Phase 1/2 clinical trial is evaluating a conditioning regimen that includes briquilimab as a potential treatment for FA patients in bone marrow failure.
  • “All three FA patients who underwent conditioning with briquilimab achieved full blood count recovery.
  • These outcomes underscore the potential for briquilimab conditioning regimen to redefine the landscape of FA therapy.

Ajax Therapeutics Appoints Dr. David Steensma as Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the appointment of David P. Steensma, MD, FACP, as Chief Medical Officer.

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the appointment of David P. Steensma, MD, FACP, as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230823046723/en/
    Ajax Therapeutics CMO David Steensma, MD, FACP (Photo: Business Wire)
    “We are very fortunate to have such a veteran hematology drug developer as David join the Ajax team as we near the clinic with our next generation Type II JAK2 inhibitor program for MPNs,” said Martin Vogelbaum, CEO of Ajax Therapeutics.
  • Dr. Steensma has published over 200 original research papers as well as numerous reviews, editorials and book chapters.
  • He received his medical degree from the University of Chicago’s Pritzker School of Medicine.

Polycythemia Vera Epidemiology Forecast 2023-2032: Cases Expected to Increase Across Regions and Genders - ResearchAndMarkets.com

Retrieved on: 
Monday, March 20, 2023

The "Polycythemia Vera - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polycythemia Vera - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The prevalence is projected to increase during the forecasted period
    In the United States, there were approximately 69,000 males and about 38,000 females affected with PV in 2022.
  • This 'Polycythemia Vera (PV)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
  • Polycythemia Vera is a rare blood disease in which the body makes excessive red blood cells.

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Retrieved on: 
Friday, February 17, 2023

The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.

Key Points: 
  • The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
  • In the follow-up data series presented, 100% total donor chimerism was achieved through six months for the first patient and at three months for the second patient.
  • Briquilimab was cleared by day 9 after dosing in both patients and no treatment-related adverse events or toxicities were observed.
  • It is also the only proven treatment for the bone marrow failure that occurs in a majority of patients with FA.

Paroxysmal Nocturnal Hemoglobinuria Market to Climb Moderately at a CAGR of 7.6% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Monday, January 23, 2023

LAS VEGAS, Jan. 23, 2023 /PRNewswire/ -- DelveInsight's Paroxysmal Nocturnal Hemoglobinuria Market Insights report includes a comprehensive understanding of current treatment practices, paroxysmal nocturnal hemoglobinuria emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • In December 2022, Novartis released the efficacy and adverse event data from the phase III APPLY-PNH trial in paroxysmal nocturnal hemoglobinuria.
  • In September 2022, efficacy and safety data from a phase III trial in paroxysmal nocturnal hemoglobinuria were released by Alexion.
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological disorder characterized by intravascular hemolysis, hemoglobinuria, hemolysis, and venous thrombosis.
  • To know more about paroxysmal nocturnal hemoglobinuria treatment guidelines, visit @ Paroxysmal Nocturnal Hemoglobinuria Management